bimagrumab and semaglutide Eli Lilly's Next-Gen Obesity Therapies: A New Era of Clinical Dominance? Why Is Eli Lilly Betting

The additional adipose tissue in heavier individuals creates a larger target for the peptide but also means more tissue requires the signal to release stored lipids

Before, I'd constantly think about snacks, but now I feel more in control

Several GLP-1 receptor agonists have demonstrated cardiovascular benefits in specific populations, with varying magnitudes of risk reduction for major adverse cardiovascular events in landmark trials

We want to help plan sponsors understand that cohort and build benefits around it, not just to reduce the likelihood of a stroke or heart attack, but to advance benefits equity within their plans

Temporary side effects, especially when first starting or increasing your dose, can include mild nausea, vomiting, or stomach discomfort